TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $25,767,113 | -68.3% | 1,225,255 | -62.9% | 0.16% | -70.9% |
| Q3 2022 | $81,312,000 | +1.7% | 3,300,009 | 0.0% | 0.53% | +17.4% |
| Q2 2022 | $79,959,000 | -6.0% | 3,300,009 | 0.0% | 0.45% | -7.2% |
| Q1 2022 | $85,041,000 | +2.6% | 3,300,009 | +23.6% | 0.49% | +21.3% |
| Q4 2021 | $82,847,000 | +67.5% | 2,669,054 | +30.9% | 0.40% | +85.7% |
| Q3 2021 | $49,464,000 | +1713.9% | 2,039,772 | +991.3% | 0.22% | +1708.3% |
| Q2 2021 | $2,727,000 | -41.6% | 186,915 | 0.0% | 0.01% | -40.0% |
| Q1 2021 | $4,667,000 | – | 186,915 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |